sftd
DPP-4 Inhibitor by Merck: JANUVIA™, Approved by the USFDA for Type 2 Diabetes
Filed in archive Treatment by Gloria Gamat on October 20, 2006
DPP-4 Inhibitor by Merck: JANUVIA™, Approved by the USFDA for Type 2 Diabetes
Belonging to a class of class of prescription medications called dipeptidyl peptidase-4 (DPP-4) inhibitors, Merck's JANUVIA™(sitagliptin phosphate) has recently been approved by the USFDA for the treatment of type 2 diabetes.

In a recommended dose of 100 mg once daily, JANUVIA™ is designed to improve blood sugar (glucose) control in patients with type 2 diabetes when diet and exercise is not enough.

However, JANUVIA™ should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, because it will not give the same effect.

Read more from Merck's press release.

Photo Credit: [NY Times]

Permalink: DPP-4 Inhibitor by Merck: JANUVIA™, Approved by the USFDA for Type 2 Diabetes
Tags: type  2  diabetes  JANUVIA  Merck 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/39879
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for DPP-4 Inhibitor by Merck: JANUVIA™, Approved by the USFDA for Type 2 Diabetes:

  • Currently 7.67/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 7.67 out of 6 vote(s) cast.
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!